<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1352">
  <stage>Registered</stage>
  <submitdate>28/07/2004</submitdate>
  <approvaldate>28/07/2004</approvaldate>
  <actrnumber>ACTRN12606000372583</actrnumber>
  <trial_identification>
    <studytitle>A study evaluating the role of docetaxel (Taxotere) in combination with thalidomide in men with hormone refractory prostate cancer</studytitle>
    <scientifictitle>A feasibility and efficacy study, evaluating the prostate specific antigen (PSA) response, of taxotere/prednisone in combination with thalidomide in hormone refractory prostate cancer</scientifictitle>
    <utrn />
    <trialacronym>ProTat</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR588</secondaryid>
    <secondaryid>Therapeutic Goods Administration (TGA): TGA 2004/172</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients will receive treatment with docetaxel 75 mg/msquared intravenously every 3 weeks (1 cycle).  On day 1 patients will commence a daily dose of prednisone 10 mg orally and a 200 mg oral dose of thalidomide given daily.  Prophylactic enoxaparin at a dose of 40 mg subcutaneous will be administered daily. Patients will continue to receive treatment until disease progression, patient intolerance or withdraw of consent. Maximum number of cycles is 10.  After study treatment discontinuation, patients will be treated by their physicians as determined by usual practice and followed for survival.</interventions>
    <comparator />
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. PSA prostate specific antigen. </outcome>
      <timepoint>Measured at baseline and 3 weekly intervals</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Tumour lesion assessment.</outcome>
      <timepoint>Measured after every second cycle for those patients with measurable disease</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. Progression free survival.</outcome>
      <timepoint>Measured form registration to documented evidence of progression</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>4. Overall survival.</outcome>
      <timepoint>Measured from registration to date of death</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Toxicity</outcome>
      <timepoint>Measured at commencement of each cycle.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Quality of life</outcome>
      <timepoint>Measured at each cycle.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologically/cytologically proven prostate adenocarcinoma2. ALl patients are males, aged 18 years or more and must have prostate adenocarcinoma that is responsive or refractory to hormone therpay.3. Prior treatment with crticosteroids is allowed.4. life expectancy greater or equal to 3 months.5. prior surgery is allowed.  At least 4 weeks must have elapsed since the completion of surgery.6. ECOG 0-27. Informed consent signed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Prior cytotoxic chemotherapy (except monotherapy with estramustine)2. prior isotope therapy3. prior radiotherapy to &gt;25% of bone marrow (whole pelvic radiation is not allowed)4. known brain leptomeningeal involvement.5. Other malignancy6. Uncontrolled medical condition7. Prior Deep venous thrombosis or pulmonary embolism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>35</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal North Shore Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Educational grant from Sanofi Aventis</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Educational grant from Pharmion</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Trials NSW</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The ProTaT trial is a phase II trial evaluating the safety and activity of the combination of docetaxel (Taxotere), prednisone and Thalidomide  in men with metastatic hormone refractory prostae cancer. The hypothesis is that the combination of a standard systemic therapy, docetaxel, with and antiangiogenic agent may improve the response rate in patients with this disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/03/2004</ethicapprovaldate>
      <hrec>0402-042M</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Haematology Oncology Clinics</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Lismore Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Port Macquarie Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Gavin Marx</name>
      <address>11/49 Plamerston rd 
Hornsby
NSW 2077</address>
      <phone>+ 61 2 94765844</phone>
      <fax>+ 61 2 94821341</fax>
      <email>gmarx@shoc.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sally McCowatt</name>
      <address>Oncology Clinical Trials Unit
Royal North Shore Hospital
St Leonards
Sydney NSW</address>
      <phone>+61 2 99265049</phone>
      <fax>+61 2 94821341</fax>
      <email>smccowatt@nsccahs.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>